Alessio Lodola

Alessio Lodola is a Full Professor at the Department of Food and Drug Sciences, University of Parma, with a career spanning over two decades in Medicinal Chemistry and Computational Drug Design. He has held academic positions since 2005, progressing from Researcher to Associate Professor (2014-2023) and Full Professor (since 2023).

His research focuses on targeted therapy for cancer, epigenetic modulators, and protein-protein interaction inhibitors with emphasis on the Eph/ephrin system. He has led projects on HDAC inhibitors, JAK3 inhibitors, and antiviral agents against SARS-CoV-2.

• 2005-2008: Researcher at University of Parma
• 2008-2013: Confirmed Researcher at University of Parma
• 2014-2023: Associate Professor at University of Parma
• 2023-present: Full Professor at University of Parma
• 2024: Delegate for Research Quality at Department

His publication trends highlight expertise in computational modeling, covalent drug design, and targeted cancer therapies, with recent work on antifibrotic agents and epigenetic modulators for FLT3/ITD acute myeloid leukemia. He has received scientific awards including the New Investigator Award 2009 (Gordon Research Conference) and EFMC Prize 2010 for young medicinal chemists.

He teaches Drug Design and Scientific Communication at the University of Parma, holding leadership roles in the Master's in Pharmaceutical Chemistry and Technology and PhD Program in Drug Sciences. He has organized international conferences like the First Congress on the Eph/ephrin System (2016) and contributed to editorial boards such as PLOS ONE.